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Introduction
Osteoarthritis (OA) is a chronic synovial joint disease, char-
acterized by two main features: (1) progressive damage of 
articular cartilage, bone remodeling, and new bone forma-
tion (osteophytes and subchondral bone sclerosis) and (2) 
synovial inflammation and fibrosis of ligaments, tendons, 
menisci, and capsules. All joints may be affected, but the 
most commonly involved are knees, hands, and hips (Fig. 
1). While chronic OA used to be regarded as a “wear and 
tear disease,” researchers now believe that low-grade 
inflammation and growth of blood vessels and nerves from 
the subchondral bone into articular cartilage, as well as met-
abolic disorders, play a major role in disease pathology.1-4 
Patients with OA suffer from pain, inflammation, and lim-
ited joint function. Pharmacological interventions are 
mostly palliative, focusing on alleviation of symptoms or 
slowing disease progression until damaged hip or knee 
joints are eventually replaced.5-10 Women are more severely 
affected than men by knee OA.11 Differences in knee anat-
omy (narrower femurs, thinner patellae, larger quadriceps 
angles, and differences in tibial condylar size), previous 
knee trauma, and genetic and hormonal influences may play 
a role. Other factors such as age and obesity are also com-
mon factors. In general, women present for treatment in 
more advanced stages of OA and have more debilitating 
pain than men. Women also have less cartilage volume, 
greater cartilage wear, and overall differences in mechani-
cal alignment.
Current Pharmacologic Therapies
Pain medications currently used to treat the symptoms of OA 
include acetaminophen, topical capsaicin, topical and oral 
nonsteroidal anti-inflammatory drugs (NSAIDs; i.e., 
naproxen and ibuprofen), and the synthetic opioids tramadol 
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Abstract
Osteoarthritis (OA) is a painful and life-altering disease that severely limits the daily activities of millions of Americans, and it is 
one of the most common causes of disability in the world. With obesity on the rise and the world’s population living longer, 
the prevalence of OA is expected to increase dramatically in the coming decades, generating burdensome socioeconomic 
costs. This review summarizes current pharmaceutical, nonpharmaceutical, and prospective new treatments for OA, with 
primary focus on the dietary supplement avocado/soybean unsaponifiables (ASU). ASU modulates OA pathogenesis by 
inhibiting a number of molecules and pathways implicated in OA. Anticatabolic properties prevent cartilage degradation by 
inhibiting the release and activity of matrix metalloproteinases and increasing tissue inhibitors of these catabolic enzymes. 
ASU also inhibits fibrinolysis by stimulating the expression of plasminogen activator inhibitor. Anabolic properties promote 
cartilage repair by stimulating collagen and aggrecan synthesis via inhibition of inflammatory cytokines such as interleukin 
(IL)-1, IL-6, IL-8, tumor necrosis factor, ERK, and prostaglandin E2. Chondroprotective effects are mediated by correcting 
growth factor abnormalities, increasing TGF-β, and decreasing vascular endothelial growth factor (VEGF) in synovial fluid. 
ASU also inhibits cholesterol absorption and endogenous cholesterol biosynthesis, which mediate reactive oxygen species 
pathology in chondrocytes. At the clinical level, ASU reduces pain and stiffness while improving joint function, resulting in 
decreased dependence on analgesics.
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and codeine. However, each of these therapies has potential 
drawbacks that may limit their widespread use. Analgesics 
can be addictive, whereas acetaminophen can have serious 
side effects, such as kidney and liver damage.12 Patients who 
do not respond to acetaminophen may be prescribed 
NSAIDs. Treatment with NSAIDs, which inhibit cyclooxy-
genases (COX1 and COX2), thereby blocking prostaglandin 
synthesis, improves quality of life and decreases pro-inflam-
matory cytokines including interleukin-6 (IL-6), vascular 
endothelial growth factor (VEGF), and tumor necrosis 
factor-α (TNF-α) in synovial fluid and mitogen-activated 
protein kinases (MAPKs) in knee OA.13 However, NSAIDs 
can also cause serious side effects, including upper gastroin-
testinal (GI) toxicity (dyspepsia, ulcers, perforation, obstruc-
tions, and bleeding) and liver dysfunction. As such, they are 
typically prescribed for the shortest possible duration at the 
lowest effective dose. To reduce the risk of these upper GI 
complications, the US FDA has approved the use of the 
NSAID HZT501 (Duexis), a drug containing 800 mg ibu-
profen, in combination with 26.6 mg famotidine, a histamine 
H2-receptor antagonist.14 Alternatively the NSAID cele-
coxib has less risk of upper GI complications by selectively 
inhibiting the isoenzyme COX-2, which is specific to 
inflamed tissue, versus COX-1, which is constitutive in 
many tissues including the GI tract. It should be noted that 
daily treatment with celecoxib is more effective in patients 
with normal body mass index (BMI) than obese patients.15
Intra-articular injection of corticosteroids (GC) is rec-
ommended to relieve inflammation and pain in OA joints. 
However, GC injections are short acting, prone to adverse 
side effects, and have limited disease-modifying effects. 
For patients with knee OA, viscosupplementation with 
hyularonin may be used to replaces shock absorbing and 
lubricant material in the joint fluid, but the effects are simi-
larly short-lived.
Current Nonpharmacologic Therapies
Currently, guidelines for OA management are available from 
numerous organizations, including the American Academy of 
Orthopedic Surgeons (AAOS), the American College of 
Rheumatology (ACR), the American Geriatrics Society 
(AGS), the American Pain Society (APS), and the 
Osteoarthritis Research Society International (OARSI) in the 
United States and the European League Against Rheumatism 
(EULAR) and the United Kingdom’s National Institute for 
Health and Clinical Excellence (NICE) in Europe. Collectively, 
these guidelines reflect the experience of physicians across a 
variety of medical disciplines. Whereas all generally use the 
same data sources (i.e., evidence-based research, expert opin-
ion, patient experience, and cost-effectiveness analysis), they 
differ in focus. For instance, the AAOS and AGS guidelines 
reflect the perspective of specialists in orthopedic surgery, 
geriatrics, and pain management, whereas the EULAR and 
OARSI guidelines primarily emphasize the findings of experts 
in rheumatology. The NICE guidelines are developed jointly 
by physicians and other health care professionals working in 
conjunction with a range of clinical researchers. In addition, 
the scope varies, with some guidelines (e.g., AAOS, ACR, 
EULAR, and OARSI) addressing specific types of OA (i.e., 
knee, hip, or hand) and others (e.g., AGS, APS, and NICE) 
addressing OA more generally. As such, recommendations 
can vary widely, for instance, guidelines for use of 
NSAIDs.10,16-19 Recommended nonpharmacologic interven-
tions range between therapeutic exercises, patient education, 
transcutaneous electrical nerve stimulation, acupuncture, 
Figure 1. Anteroposterior and cross-table lateral of knee 
osteoarthritis (OA). Symptomatic knee OA typically presents 
with narrowing of the joint space and bone spurs (arrows). 
(A and B) During the development of OA, articular cartilage 
breaks down over time and becomes thin. As a result, the bone 
surfaces rub against each other, further damaging the cartilage 
and bone and causing pain. (C and D) Joints with late-stage OA 
are often painful, warm to the touch, possibly red, swollen, have 
subchondral cysts, and notable loss of function.
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orthotics and insoles, heat and cryotherapy, patellar tapping, 
and weight control. In an effort to evaluate these varying 
guidelines, the Appraisal of Guidelines Research and 
Evaluation (AGREE II) scored 17 clinical practice guidelines 
(CPGs) including EULAR, NICE, OARSI, AAOS, and ACR, 
on six different measures: D1, scope and purpose; D2, stake-
holder involvement; D3, rigor of development; D4, clarity 
and presentation; D5, applicability; and D6, editorial indepen-
dence.20 The general clinical management recommendations 
tended to be similar among high-quality CPGs, although 
interventions addressed varied. Nonpharmacological man-
agement interventions were superficially addressed in more 
than half of the selected CPGs.
Prospective New Treatments
New noninvasive, disease-modifying therapies for OA are 
lacking and needed by millions of patients. A number of 
prospective new treatments targeting pro-inflammatory 
mediators, cytokines, bone turnover, and angiogenic and 
neurogenic factors are being investigated, with varying suc-
cess in clinical trials and clinical use.21
Interleukin-1 (IL-1) may prove an effective target, as 
IL-1 induces matrix metalloproteinase (MMP) production, 
resulting in the degradation of aggrecan and other matrix 
constituents. IL-1 also induces high levels of COX2 and 
prostaglandin E2 (PGE2), which may explain the pain asso-
ciated with OA degeneration.22 The drug diacerein, an 
inhibitor of IL-1, may modify both disease symptoms and 
disease structure in OA. Oral diacerein has proven effective 
in reducing pain, although evidence from clinical trials and 
scientific literature suggest that the effectiveness in OA is 
weak. It can be used in conjunction with NSAIDs or visco-
supplementation therapies for additive effects due to its 
alternative mechanism of action. The most common side 
effects of diacerein are gastrointestinal, such as diarrhea, 
and changes in the color of urine. Meanwhile, the IL-1-
receptor antagonists anakinra and orthokin are reported to 
improve Western Ontario and McMaster Universities 
Arthritis Index (WOMAC) scores.23-25 In addition, the 
IL-1β antibody “gevokizumab” is in phase II clinical trials 
for safety and biological activity in the treatment of hand 
OA.26,27
Nerve growth factor (NGF) has also been recognized as 
an important mediator of chronic pain in OA. Tanezumab, a 
monoclonal antibody against β-NGF receptor tyrosine 
kinase (TrkA), inhibits NGF action and reduces pain in 
patients.28 Two randomized phase III clinical trials indicate 
that tanezumab provides superior pain relief while improv-
ing physical function and global disease assessment scores 
in patients with painful hip OA.27,29-33 Although in most 
cases tanezumab is well tolerated, the unexpected occur-
rence of rapid destructive arthropathies suggests there may 
be safety issues. Alternatively, using the drug adalimumab 
to inhibit TNF-α, which upregulates β-NGF, does not 
improve global disease assessment scores in OA of the 
hand.27,34
Several studies have explored therapies aimed at modi-
fying bone turnover for treatment of OA. Strontium ranelate 
(SrRa), an element similar to calcium, is easily taken up by 
the body and incorporated into bones in place of calcium. 
SrRa is currently indicated for the prevention of fracture in 
severe osteoporosis. The SEKOIA (SrRa Efficacy in Knee 
OsteoarthrItis triAl) trial, a 3-year randomized, double-
blind, placebo-controlled trial, evaluated the efficacy, 
safety, and disease-modifying effects of SrRa given at 1 to 
2 g/day in patients with knee OA. Magnetic resonance 
imaging (MRI) data indicate that SrRa significantly reduced 
cartilage volume loss and bone marrow lesion progression. 
Symptoms also improved in terms of pain and physical 
function after 6 and 12 months, respectively,35 although 
treatment was deemed safe and well tolerated. These data 
indicate that SrRa could be a promising new symptom and 
disease-modifying treatment for OA. Additionally, there is 
a need for further investigations to establish the optimal 
dosage and to better clarify the mechanism of action of 
SrRa in OA.35-37 Several clinical studies have investigated 
the effects of anti-resorptive therapies such as bisphospho-
nates on OA symptoms. A study by Carbone et al. found 
that alendronate (ALN) use in OA patients decreased bone 
abnormalities and attenuated knee pain, yet cartilage degen-
eration was still present in the MRI scans of treated 
patients.38 Spector et al. determined that risedronate use led 
to significant improvements in WOMAC scores and preser-
vation of knee joint space compared with placebo in a 
1-year randomized control trial involving patients with 
moderate OA.39 However, a 2-year randomized control trial 
of risedronate treatment revealed contradictory results, with 
no significant improvement of WOMAC score or joint 
space retention in the knee.40 Similarly, Nishii et al. 
observed no inhibition of OA progression in treated hip OA 
patients after 2 years of ALN treatment.41 Therefore, in 
spite of the growing body of clinical work investigating the 
subject, no definitive conclusion can be reached on the 
practicality of using bisphosphonates to treat patients with 
OA.
Antidepressants have shown promising preliminary 
results for treatment of pain associated with OA by increas-
ing serotonin levels in the brain. Serotonin-norepinephrine 
reuptake inhibitors duloxetine (Cymbalta) and milnacipran 
significantly improve pain in OA.27,42 An open-label trial 
also suggested analgesic effectiveness of methotrexate, an 
anti-inflammatory drug that acts by inhibiting the metabo-
lism of folic acid, demonstrating that up to 20 mg/week for 
6 months achieved OARSI responder criteria in knee OA 
and warranted a randomized controlled trial.43
Other treatments are aimed at improving disease pathol-
ogy by building cartilage. The small molecule kartogenin 
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was identified in an image-based high-throughput screen to 
promote chondrocyte differentiation. It shows chondropro-
tective effects in vitro and is efficacious in two animal mod-
els of OA. Kartogenin induces chondrogenesis by disrupting 
the interaction between filamin A and the transcription fac-
tor core-binding factor b subunit (CBFβ), thereby altering 
CBFβ-RUNX1 and possibly RUNX2 transcriptional pro-
grams.44 Autologous injection of platelet-rich plasma (PRP) 
has been used to stimulate cartilage repair and healing in 
OA patients,27,45,46 but the presence of other growth factors 
in PRP may be problematic. Furthermore, bone morpho-
genic protein 7 (BMP7), FGF-8, and botulium toxin A 
(BoNT-A) are used in the treatment of knee OA.47 BoNT-A 
has an analgesic effect by temporarily suppressing acetyl-
choline secretion at presynaptic nueuromuscular junctions 
and appears to be effective and safe for the management of 
advanced knee OA. However, these results cannot be gener-
alized to patients with mild knee joint pain or nonspecific 
soft tissue pain in the knee joint region. Further research is 
necessary to investigate possible complications such as 
aggravation of infection, effect on muscle strength, and 
neuropathic joint degeneration.
Current nonsurgical and reconstructive surgical thera-
pies are unsuccessful in reversing OA. Recently, a phase I 
trial was reported in which chondrocytes were modified via 
intra-articular DNA injection to produce TGF-β1 in patients 
with advanced knee OA.48 Intra-articular injection of adi-
pose-derived stem cell (ADSC) therapy in a new European 
program is also under investigation.49 ADSC induced the 
release of trophic factors that exerted anti-inflammatory 
effects on both synoviocytes and chondrocytes, with no 
MMP1, MMP3, or MMP13 production, suggesting safe and 
effective use of ADSCs for clinical applications. However, 
both treatments need proof-of-concept studies in larger 
patient populations. Alternatively, intra-articular injection 
of human mesenchymal stem cells can lead to articular car-
tilage protection through the SDF-1/CXCR4 axis.50-54
Dietary Supplements
Natural products can be safer than prescription medications 
with less undesirable side effects. Dietary supplements 
including avocado soybean unsaponifiables (ASU), chon-
droitin sulfate, hyaluronan, and glucosamine sulfate have 
been reported to modify EULAR symptoms for the treat-
ment of OA.55,56 They are used to treat mild to moderate 
pain and alleviate symptoms to reduce the consumption of 
NSAIDs.
Several trials for chondroitin sulfate, glucosamine sul-
fate, and hyaluronan (C
14
H
21
NO
11
)n are in process.56,57 
Chondroitin sulfate, glucosamine sulfate, and hyaluronan 
are building blocks for proteoglycan synthesis, and major 
constituents of the extracellular matrix in cartilage and 
synovial fluid.58 They are produced by chondrocytes and 
syonivocytes or obtained through diet.59-65 Hyaluronan and 
hyaluronic acid (Hyalgan hylan-GF20/Synvisc) can be 
injected into the knee joint of patients with OA who cannot 
tolerate NSAIDs or are awaiting joint surgery.66 A recent 
report indicates that viscosupplementation with Hylan-GF20 
slows type II collagen degradation and joint inflammation 
in patients with OA.67 However, Hylan-GF20 was not pres-
ent in granulomas, an indicator of inflammation, raising the 
question of clinical significance in pain reduction.68 Also, 
viscosupplementation with hyaluronic acid itself does not 
significantly improve disease outcome, and little is known 
about long-term effects.
The efficacy of glucosamine and/or chondroitin in treat-
ing knee OA pain was evaluated in the Glucosamine/
Chondroitin Arthritis Intervention Trial, funded by the 
National Center for Complementary and Alternative 
Medicine and the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases. Patients were treated 
daily for 24 weeks with glucosamine alone (1,500 mg), 
chondroitin sulfate alone (1,200 mg), glucosamine and 
chondroitin sulfate combined (same doses), a placebo, or 
celecoxib (200 mg), which served as a positive control. 
Although there were no statistically significant differences 
between any of the experimental treatments and the placebo 
overall, patients with moderate-to-severe pain given both 
glucosamine and chondroitin sulfate did show improvement 
(79% experienced pain reduction vs. 54% for placebo). 
Because of the small size of this subgroup, these findings 
should be considered preliminary and need to be confirmed 
in further studies.61,69-71
Glucosamine does not appear to slow arthritis progres-
sion over the long term and has many potential complica-
tions. The most common adverse effects are epigastric pain 
or tenderness, heartburn, diarrhea, and nausea. Glucosamine 
also may cause allergic reactions in patients with seafood 
allergies, as a product of lobster, crab, and shrimp shells. 
Glucosamine may interact with various pharmaceuticals, 
such as warfarin (Coumadin) and diabetes medications, 
dangerously modifying their efficacy.
Similarly, chondroitin sulfate appears not to provide 
meaningful benefit for patients with OA, and their combi-
nation has not proven effective for either pain management 
or functional improvement. OARSI and NICE no longer 
recommend the use of glucosamine or chondroitin sulfate 
alone, or in combination, if no effects are observed after 6 
months or radiographic changes are marginal.55,61,62,72
A network meta-analysis of 10 trials in 3,803 patients by 
Juni and collaborators in 2012 found no clinically signifi-
cant improvements in OA pain alleviation or JSN parame-
ters with glucosamine, chondroitin, or combined treatment 
compared with placebo. Despite these results, many patients 
believe otherwise, potentially due to the natural course of 
disease, regression to the mean, or the placebo effect. The 
authors conclude that such patients should be permitted to 
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use these supplements if they cover the cost themselves, 
since neither of these preparations was found to be 
dangerous.73
SierraSil is a dietary supplement marketed for joint pain 
relief that is derived from the mineral-rich clay found in the 
high Sierra Mountains in the United States. Clinical trial 
testing short-term efficacy of SierraSil at doses of 2 and 3 g 
per day failed to show sustained benefits over placebo, and 
iron toxicity has been reported.74
Some OA patients experience pain relief from topical 
creams containing capsaicin, the active component of chili 
peppers. However, use of these creams may introduce side 
effects such as burning, stinging, and redness of the skin 
and eyes.10
Avocado and Soybean Unsaponifiables
Avocado/soybean unsaponifiables are natural vegetable 
extracts made from avocado and soybean oils, consisting of 
the leftover fraction (approximately 1%) that cannot be 
made into soap after saponification. ASU is composed of 
one third avocado and two thirds soybean unsaponifiables 
(A1S2U). The major components of ASU are phytosterols 
β-sitosterol, campesterol, and stigmasterol, which are rap-
idly incorporated into cells. ASU is a complex mixture of 
many compounds including fat-soluble vitamins, sterols, 
triterpene alcohols, and possibly furan fatty acids. The iden-
tity of the active component(s) remains unknown. The ste-
rol contents of ASU preparations are the primary contributors 
to biological activity in articular chondrocytes.75 Preclinical 
in vitro and in vivo studies have demonstrated that ASUs 
have beneficial effects on OA.76-90
ASU possesses chondroprotective, anabolic, and anti-
catabolic properties. It inhibits the breakdown of cartilage 
and promotes cartilage repair by inhibiting a number of 
molecules and pathways implicated in OA (Tables 1 and 2). 
ASU stimulates the synthesis of collagen and aggrecan by 
inhibiting inflammatory cytokines such as IL-1, IL-6, IL-8, 
TNF, and PGE2 through modulation of NF-kappaB.91-94 
The combination of ASU and epigallocatechin gallate 
(EGCG; a major component of green tea catechins) affects 
an array of inflammatory molecules including expression of 
COX-2 and production of PGE2 in chondrocytes.95 COX-2 
regulates the production of PGE2; both are mediators 
involved in the process of cartilage breakdown. ASU also 
inhibits the release and activity of collagenase (MMP2) and 
stromelysin 1 (MMP3) in cultured chondrocytes,77,96 
increases tissue inhibitors of metalloproteinases (TIMP-
1),79,97 and inhibits IL1-induced ERK but not p38 or JNK in 
chondrocytes in vitro.86
In vitro studies show that ASU inhibits fibrinolysis by 
stimulating the expression of plasminogen activator inhibi-
tor (PAI-1).98 PAI-1 inhibits tissue plasminogen activator 
and urokinase (uPA), thereby blocking plasminogen activa-
tion and inhibiting fibrinolysis (the physiological break-
down of blood clots). This fibrinolytic and tissue destructive 
proteinase cascade may play a role in OA joint inflamma-
tion via altered expression of uPA receptors.99
ASUs alter growth factor levels implicated in OA patho-
genesis, increasing TGF-β1 and TGF-β2 in the canine knee 
joint fluid,100 to repair cartilage and decreasing VEGF, 
which is markedly elevated in synovial fluid of patients.13,97 
In a study of implant osseointegration in rat tibiae, ASU 
administration improved markers of bone growth, including 
Table 1. Stimulatory Effects of Avocado Soybean Unsaponifiable on Anti-Inflammatory, Anabolic Mediators That Protect Against 
Osteoarthritis.
Molecular Mediator Target Tissue/Organ Organism Assay References
Collagen synthesis Articular synoviocytes, 
chondrocytes, skin 
fibroblasts
Rabbit, bovine, 
human
In vitro 81, 84, 93
Collagen II mRNA Chondrocytes + 
subchondral bone 
osteoblasts (SBO)
Human In vitro 84
Agreecan proteoglycan Chondrocytes, SBO Equine, human In vitro 84, 94
TGF-β1 Knee joint fluid, 
osseointegration in tibiae
Rat, canine In vivo, in vitro 84, 98, 100, 101
TGF-β2 Knee joint fluid Canine In vitro, in vivo 98, 100
TGF-β3 Chondrocytes + SBO Human In vitro 84
BMP-2 Osseointegration in tibiae Rat In vivo 101
Osteocalcin Chondrocytes + SBO Human In vitro 84
Chondroprotector Bone implant Rat In vivo 96
Delayed destruction of the 
joints
Radiological evaluation Human In vivo 81
Plasminogen activator 
inhibitor 1 (PAI-1)
Chondrocytes, osteoblasts Bovine In vitro 98
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bone morphogenic protein 2 (BMP-2) and transforming 
growth factor beta 1 (TGF-β1), though histomorphometric 
analysis of implant osseointegration was only slightly 
improved.101 ASU also inhibits cholesterol absorption and 
endogenous cholesterol biosynthesis.102 Sixty percent of 
patients with OA exhibit high levels of oxidized low-den-
sity lipoproteins (oLDL) in serum, which mediates reactive 
oxygen species (ROS) activity in chondrocytes and OA 
pathology.103,104 Treating patients with a daily dose of 300 
mg ASU for 3 months decreased oLDL levels.105
At the clinical level, ASU reduces pain and stiffness while 
improving function in joints, resulting in decreased depen-
dence on analgesics. ASU efficacy and safety during and 
after treatment have been assessed in various randomized, 
double-blind, multicenter trials in patients with symptomatic 
knee or hip OA. Two studies conducted over a 3-month 
period report that standard treatment with 300 mg/day of 
ASU improved indices of pain, stiffness, and physical func-
tion, as measured by WOMAC, and decreased analgesic drug 
demanded in patients with OA.106-109 A third trial conducted 
over 6 months reports similarly improved function compared 
with placebo, measured by the Lequense Functional Index, 
with persistent effects after termination of treatment.108 In a 
6-month trial on patients with femorotibial gonarthrosis, 
ASU was as effective as 400 mg of chondroitin sulfate three 
times per day, as measured by WOMAC.110 Most recently, a 
3-year randomized trial on patients with hip OA, performed 
under the ACR criteria (minimum of 1-4 mm hip JSW on the 
pelvic radiographs), reports excellent safety, but no signifi-
cant reduction in the mean rate of JSN after 1 year. However, 
analyzing the results under different parameters reveals a sig-
nificant 20% reduction in the rate of progression in patients 
with severe hip OA (P = 0.04), indicating a potential structure 
modifying effect of ASU,111 as confirmed in the ERADIAS 
Table 2. Inhibitory Effects of Avocado Soybean Unsaponifiable on Inflammatory and Catabolic Mediators of Osteoarthritis.
Molecular Mediator Target Tissue/Organ Organism Assay References
Interleukin-1 beta (IL-1β) Synoviocytes, 
chondrocytes
Mice, rabbit, 
human
In vitro 77, 81, 116
Interleukin-4 (IL-4) Chondrocyte In vitro  
Interleukin-6 (IL-6) Chondrocyte Human In vitro 81, 92
Interleukin-8 (IL-8) Chondrocyte Human In vitro 92
Macrophage inhibitory 
protein-1beta (MIP-1β)
Chondrocyte Human In vitro 87, 116
MMP-2 (also known 
as collagenase, or 
gelatinase-2)
Fibroblasts, chondrocyte Human In vitro 79, 81, 92
MMP-3 (also known as 
stromelysin)
Fibroblasts chondrocyte 
+ subchondral bone 
osteoblasts (SBO)
Mice, human In vitro 79, 81, 84, 86, 92, 101
MMP-13, collagenase-3 Chondrocytes, 
chondrocytes + SBO
Mice, human In vivo 84, 86
Tissue inhibitors of MMP 
(TIMP-1)
Fibroblasts + SBO Human In vitro 79, 84
COX2 Chondrocytes, monocyte/
Macrophage-like cells, 
chondrocytes + SBO
Equine, 
human
In vitro 84, 116, 115
Prostagladine-2 (PGE2) Hyalin chondrocytes, 
monocyte/macrophage-
like cells
Mice, equine, 
human
In vitro 86, 92, 116
NF-κB Hyalin chondrocytes, 
nuclear translocation 
of p65
Mice, equine, 
human
In vitro 86, 115
ERK1/2 Hyalin chondrocytes Mice, human In vitro 86
TNF-α Chondrocytes Human In vitro 84
iNOS Chondrocytes, monocyte/
macrophage-like cells
Human In vitro 84, 116
NO Chondrocytes, monocyte/
macrophage-like cells
Human In vitro 116
oLDL Osteoblasts Human Serum 104
Fibronectin Chondrocytes Human In vitro 81
Alkaline phosphatase Osteoblasts Human In vitro  
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study. In a clinical trial of patients with hip OA, the effects of 
ASU treatment over 3 years were evaluated by radiography 
to identify joint pathology and disease progression on the 
structural level. Although JSN was not statistically signifi-
cant between ASU and placebo treatment, secondary analysis 
of disease progression, measured by JSN (0.5 mm) or total 
hip replacements, indicated 20% improvement with ASU 
(42.2% vs. 51.4% of placebo group, P = 0.054). Computerized 
image analysis also showed significant histological differ-
ences not detectable by traditional scoring methods.112 In 
sheep, ASU treatment following cartilage insult improved 
articular integrity, as measured by toluidine blue staining, 
after 6 months compared with untreated animals. These 
improvements were the result of decreased catabolism and 
increased anabolism of cartilage by ASU.78 Indeed, ASU 
reduces inflammation-mediated cartilage degradation by 
reducing IL-1, PGE2, and MMP-3 production, while also 
inducing proteoglycan, noncollagenous protein (NCP), and 
collagen synthesis within 72 hours of administration to 
bovine cells in culture.75 A recent study in patients with non-
specific dorsalgia demonstrated analgesic effect of 
Piascledine with positive outcome after 1 month.113 However, 
a randomized, double-blind, placebo-controlled clinical trial 
carried out in 14 obese adult volunteers over 3 months reports 
no significant effect on these parameters, as measured by 
hyperglycemic–hyperinsulinemic clamp technique.114
Four double-blind placebo-controlled randomized human 
clinical trials (RCTs) evaluate ASU’s impact on knee and hip 
OA.109 Two of these indicated that ASU treatment decreased 
NSAID intake over 3 months.106,107 Another found that ASU 
improves LFI compared with placebo over the course of 6 
months, and also that improvements took 2 months to take 
effect, and subside after treatment ended.108 Alternatively, a 
long-term study indicated no significant difference in JSN, 
or other parameters of disease, after 2 years of ASU treat-
ment,80 indicating that the beneficial impact of ASU on OA 
may be limited to short-term effects. However, this study 
also focused on identifying structure-modifying effects, ver-
sus symptom-modifying effects; although these two differ-
ent measures of OA severity often correlate, ASU may affect 
each uniquely. Evidence for symptom-modifying effects of 
ASU is much stronger, and thus an alternative explanation 
for these contradictory findings is that while ASU does not 
improve structural damage of OA, as measured in this study, 
it does improve symptoms such as pain and mobility, as 
measured in previous studies.82 In a study of chronic nonspe-
cific back pain, treatment with ASU (piascledine) combined 
with the NSAID artrosiline (320 mg/day) showed significant 
analgesic effect over NSAID treatment alone. The positive 
effect of ASU was demonstrated after 1 month of treatment. 
The authors suggest that further RCTs are needed to confirm 
results. To this end, the ERADIAS trial determined whether 
ASU Expanscience treatment slowed the radiological pro-
gression of hip OA.113 As for safety, none of the four RCTs 
reported significant differences in adverse effects between 
ASU and placebo.
Factors like BMI, severity of disease, and activity level 
may influence the effect of ASU, as these conditions exac-
erbate inflammatory conditions and mechanical stresses 
that contribute to OA. Adipose tissue plays an important 
role by producing metabolic factors with catabolic and 
pro-inflammatory properties, including cytokines, chemo-
kines, and adipokines (IL-6 and TNF-α, IL-8, IFN-γ), 
which orchestrate pathophysiological processes in OA. 
Soluble mediators produced by adipocytes may also mod-
ulate chondrocyte metabolism and contribute to cartilage 
degradation. ASU may counteract these inflammatory 
processes by inhibiting the translocation of the transcrip-
tion factor NF-κB from the cytoplasm to the nucleus, 
which controls transcription of many pro-inflammatory 
factors (Table 2).86,115 As such, ASU acts as an anabolic 
agent in vitro, reducing the production of pro-inflamma-
tory mediators, including IL-1, IL-6, IL-8, macrophage 
inflammatory protein-1, NO, MMP-13, TNF-α, and 
COX2/PGE288,94,115,116 from various cell types (Table 1). 
In mice, ASU decreases pro-inflammatory interferon-γ 
(IFN-γ) and IL-4 production, in the context of parasitic 
diseases.117,118 Although more studies need to be con-
ducted to show the effects of ASU in patients with varying 
BMI, the anti-inflammatory effects of ASU are likely to 
protect cartilage from obesity-associated inflammatory 
degradation and improve OA symptoms. Indeed, ASU sig-
nificantly decreased the rate of OA progression to 40% 
compared with 50% in the placebo group in one study.111 
However, this study showed that ASU did not influence 
the rate of OA progression in the obese subset of patients 
with mean symptom duration 4 and BMI of 27 kg/m2.
However, excessive inflammation associated with obe-
sity may also impede efficacy, as it does with celecoxib 
(NSAID) treatment, which is not as effective in obese 
patients (BMI in excess of 30 kg/m2).119 The influence of 
obesity, and how it influences ASU efficacy, may also 
depend on the parameters used to measure and define dis-
ease. In a study examining the relationship between BMI 
and OA in patients scheduled to undergo hip replacement, 
increasing BMI was associated with increasing levels of 
pain and functional disability, but not radiographic joint 
damage. Thus, obesity might influence some aspects of 
disease and treatment but not others. This should be taken 
into account when designing and assessing studies intended 
to examine the impact of obesity on treatment efficacy.119
ASU has anti-inflammatory effects in mice when admin-
istered in conjunction with the anti-parasitic drug 
Praziquantel, reducing inflammatory cytokines IFN-γ and 
IL-4, as well as granuloma size, while increasing cidal 
activity.117,118 ASU also protects gingival elastic fibers from 
degradation by human leukocyte elastase,120 hypodermati-
tis,121 and ischemic damage.122
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A recent electronic database analysis demonstrated the 
benefits and harms of oral medicinal plant products in treat-
ing OA. The authors used standard methods for trial selection 
and data extraction, and they assessed the quality of the body 
of evidence using the GRADE approach for major outcomes 
such as pain, function, radiographic joint changes, quality of 
life, withdrawals due to adverse events, total adverse events, 
and serious adverse events. The ASU product Piasclidine 
formed a small and clinically questionable improvement in 
symptoms, compared with placebo after 3 to 12 months treat-
ment. Radiographic joint changes, as change in joint space 
width (JSW), did not differ between ASU 300 mg treatment 
and placebo. Moderate-quality evidence from a single study 
confirmed possible benefits of ASU 600 mg over placebo. 
There is no evidence that Piasclidine significantly improves 
joint structure, and limited evidence that it prevents joint 
space narrowing. The authors suggest further investigations 
are required to determine optimum daily doses producing 
clinical benefits without adverse events.123
ASU is considered as drug in most countries and is there-
fore prescribed by physicians. However, in the United 
States it is classified as dietary supplement and can be pur-
chased as over-the-counter supplements, Avoca ASU (ASU-
NMX1000, Nutramax Laboratories Inc., Edgewood, MD) 
and Maximize ASU 300/SierraSil (Maximum International 
Inc., Pompano Beach, FL). Avoca ASU, a combination of 
ASU and glucosamine sulfate, has been shown to suppress 
TNF-α, IL-1β, COX2, iNOS, PGE2, NF-κB activation and 
nitrite production in articular chondrocytes and monocytes/
macrophages, reducing pain and inflammation in OA 
patients.115,116,124 However, conflicting reports indicate the 
complete absence of specific ASU molecules in Avoca ASU 
when compared with Piascledine.75,125-127
Questions remain about the efficacy and safety of ASUs 
for treatment of OA (Table 4). Macaigne and colleagues 
published a case report in 2004 describing a female with 
lymphatic colitis associated with Piascledine treatment.128 
Further prospective multicenter studies are warranted to 
investigate whether other microscopic colitis cases129 are 
observed in patients treated with Piascledine. Avoca ASU 
that contains glucosamine can induce allergic reaction in 
people with shellfish allergy. Even in very small quantities, 
these people may experience mild symptoms, such as hives 
or nasal congestion, or more severe, even life-threatening, 
symptoms.
An alternative ASU formulation is Arthrocen (Pharmin, 
USA, LLC, San Jose, CA). Arthrocen is an extract from 
avocado and soybean oils that does not contain any ingredi-
ents of animal origin, artificial flavor, sweetener, preserva-
tive, or color. Each capsule contains 100 mg unsaponifiable 
persea gratissima unsaponifiable (avocado) and 200 mg 
unsaponifiable glycine max (soybean) extracts, silica, mag-
nesium stearate (E470b—manufactured from vegetable 
oil), and gelatin fines.
In general, the FDA does not hold dietary supplements to 
the stringent standards of pharmaceutical manufacture. If 
ASU is to be widely used for the treatment of OA, serious 
consideration should be given to their current regulatory sta-
tus in order to ensure potency, purity, and as well as the 
excipients. Many studies have demonstrated substantial 
variation between the content listed on the labels of these 
products and the actual content. The sterols content of ASU 
have been demonstrated to have biological activities in cul-
ture and in animal models. This approach allowed us to com-
pare the contents of three commercial supplements (Fig. 2). 
We found multiple peaks were present in the Piascledine-300 
(Expanscience) mass spectrometry analysis (Agilent 7890 
GC System, 7693 Auto Sampler, Agilent VL MSD with tri-
ple Axis Detector, Brea, CA), compared to the Arthrocen 
300 mg (PharminUSA) or ASU300-Avocado Soy 
Unsaponifiable with Sierra 600 mg (Maximize, Maximum 
Int.) preparations (Fig. 2, Table 3). Similar results were 
found for Piascledine-300,75 with mass spectra sterol content 
Figure 2. Gas chromatography–mass spectrometry analysis of 
major sterol components of Piascledine 300, Avocado 300 Soy 
Unsaponifiable with Sierra 600 mg, and Arthrocen 300. Control 
sample exhibited characteristic peaks corresponding to 1 = 
Dihydrocholesterol (5α-Cholestan-3β-ol; internal control; Sigma 
Aldrich), 2 = Brass (Brassicasterol), 3 = Camp (Campesterol), 
4 = Stigmn (Stigmastanol), 5 = β-Sito (β-sitosterol), 6 = Stigma 
(Stigmasterol).
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, sitosterol, stigmasterol, campesterol, 
squalene, β-tocopherol, desmethyl tocopherol, oleic acid 
docosane, α-amyrin, and cholesterol. In two letters to the 
editor, Msika et al.126 and Henroitin125 claimed that the exact 
Table 3. Content Analysis of Supplements Containing Avocado Soybean Unsaponifiable.
Company/Manufacturer Brand Name Dosage Form Other Ingredients Excipients on the Label
Nuramax Laboratories, Inc. Avoca ASU Avocado/Soybean 
Unsaponifiables, non-
shellfish glucosamine, 
NMX1000
OptiMSM  
 Methylsulfonylmeth  
 Green tea extract  
Helseudsalg Faaborg Denmark AvoSol Avocado 100 mg/Soy 200 
mg Unsaponifiables
Vitamin C 30 mg Glucose syrup, ox gelatin, 
soy protein isolate, extract 
rich in tocopherol, silicon 
dioxide, magnesium salts 
from fatty acids
Dr. Theos Official, USA Avosoy Avocado-Soybean 
Unsaponifiables
Vitamin C 60 mg Cellulose, dicalcium 
phosphate, sodium 
croscarmellose, silicon 
dioxide, gum acacia, 
vegetable stearic acid, film 
coating, magnesium stearate
 Vitamin E 30 U  
 Manganese 2 mg  
Dr. Theos Official, USA AvosoyComplete Avocado-Soybean 
Unsaponifiables 300 mg
Vitamin C 60 mg  
 Glucosamine 1,500 mg Vitamin E 30 U  
 Porcine chondroitin 800 mg Manganese 2 mg  
Swanson Health Products, 
Fargo, ND, USA
AvoVida 100 mg Unsaponifiables 
Persea gratissima
30% β-sitosterol, 
campesterol, 
stigmasterol
Soy protein isolate, mixed 
tocopherols, silica
 Glycine max Microcrystalline cellulose 
(plant fiber), gelatin, 
magnesium stearate
Pharmin, USA, LLC, 
Formulation Technology, 
USA
Arthrocen 300 mg Avocado 100 mg/Soy 200 
mg Unsaponifiables
Persea gratissima Silica, magnesium stearate 
(E470b manufactured from 
vegetable oil), and gelatin 
fines
 Glycine max  
Nuramax Laboratories, Inc. Cosamin ASU Avocado/Soybean 
Unsaponifiables
Glucosamine Sulfate  
 Chondoitine Sulfate  
Maximum International, USA Maximize ASU300-Avocado Soy 
Unsaponifiables
Iron: 1.1 mg (from 
SierraSil)
Microcrystalline 
cellulose, maltodextrin, 
croscarmellose sodium, 
silicon dioxide, stearic 
acid, hydroxypropylm 
ethylcellulose, 
hydroxypropylcellulos, 
magnesium stearate, 
polyethylene glycol
 SierraSil: 600 mg Iron toxicity 
recommendation on the 
container
 
Expanscience Lab, 
Courbevoie, France; 
Pharmascience, Montreal, 
Canada; Pharma Inv., Chile 
SA, Santiago; Solvay Ins.; 
Biol. Chenioterapicosells; 
Microsules y Bernabo 
Siegfried, Rhein
Piascledine 300 Avocado/Soybean 
Unsaponifiable
Not described Butylated hydroxytoluene 
(BHT) 0.05 mg/capsule
 Colloidal anhydrous silica
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ingredients and preparation of ASU-Expanscience was an 
intellectual proprietary, protected by patent. Msika further 
emphasized that the tocopherols, sterols, and patented spe-
cific molecules from avocado contribute to the originality of 
the product, different from natural avocado unsaponifiables. 
In contrast, they analyzed Dasuquin with MSM, Dasuquin, 
and Avoca ASU (Nutramax), and compared them with ASU 
Expanscience. The analyses revealed content of products 
were significantly different from those indicated on the 
Nutramax labels—with no citrostadienol, and brassicasterol 
present in ASU Expanscience. Contrary to that they found 
contents included high level of rapeseed oil and unsaponifi-
ables products with very low tocopherol, and without 
respected ratio of 1:2 for avocado to soybean unsaponifi-
ables. The original ASU Piascledine 300 pills contains 100 
mg of avocado unsaponifiables and 200 mg of soybean 
unsaponifiables. The difference in sterol content is based on 
the A/S ratio and avocado-specific modified unsaponifiables 
obtained by a patented process. Henrotin et al. have shown 
ASU effects are best when the ASU ratio is 2:1.92 In support, 
Henroitin et al. recommended additional studies to ensure 
efficacy of Nutramax products.125 These issues and reported 
adverse effects of ASU (Table 4)128,130 raises concerns about 
the content and purity of ASU supplements on the market, 
with implications for patient safety.
Conclusion
Osteoarthritis inflicts pain and physical limitation on millions 
of people. Improving joint function and patient activity is a cen-
tral public health concern to improve quality and length of life. 
The aim is not only to treat pain but also to prevent the onset of 
disease. There is no cure for OA, and even symptomatic treat-
ment options are scarce, dominated by pain management and 
surgical intervention. ASUs may prove to be an effective treat-
ment option for symptomatic OA, as they have been shown to 
possess chondroprotective, anabolic, and anticatabolic proper-
ties, as well as anti-inflammatory properties. At the clinical 
level, ASUs reduce pain and stiffness while improving joint 
function. Importantly, ASUs are a natural, slow-acting agent 
that do not merely address acute pain but actively prevent pro-
gression of OA symptoms. Further studies are required to deter-
mine the specific mechanisms and target molecules of ASU 
function on OA at the cellular and metabolic level.
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Table 4. Adverse Effects of Avocado Soybean Unsaponifiable.
Organ Side Effects Frequencies Drug Withdrawal References
Skin Eczema 32.5% 130
 Hives  
 Photosensitivity  
 Hypersensitivity 
syndrome
 
Liver Liver injury 16.2% Return to normal 130
 Bilirubin  
 ALKP  
 GGTP  
Gastrointestinal Regurgitation 12% Return to normal 106, 129, 130
 Heartburn  
 Nausea  
 Epigastric pain  
 Dyspepsia  
 Diarrhea  
 Constipation  
 Microscopic colitis  
Coagulation Platelets 6.8% 130
ALKP = alkaline phosphatase; GGTP = gamma-glutamyl transpeptidase.
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